HeartSciences Inc.
HSCSDrugs in Pipeline
56
Phase 3 Programs
24
Upcoming Catalysts
4
Next Catalyst
This month
Market Overview
Stock performance and key metrics
4 upcoming, 1 past
Dapagliflozin 10 MG [Farxiga] Phase 2 Est. Readout
Estimated primary completion for Dapagliflozin 10 MG [Farxiga] trial (NCT05719714) in Chronic Kidney Diseases. Topline data typically follows completion by weeks to months.
Source3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
UFH 250 U/kg or LMWH 100 U/kg sc twice daily
Venous Thromboembolism
LY3819253
Covid19
niacin
Cardiovascular Diseases
Eszopiclone
Sleep Apnea
Short storage RBC age
Anemia
Esomeprazole
Asthma
Tacrolimus
Leukemia, Myelocytic, Acute
tissue plasminogen activator
Myocardial Infarction
Hydrocortisone
Infant, Newborn
Omega-3 fatty acids (fish oil)
Cardiovascular Disease
daily fluticasone propionate
Asthma
Furosemide-Q12 hour bolus
Heart Failure
Vitamin D ergocalciferol
Renal Function
Secondary Prophylaxis
Rheumatic Heart Disease
Sulfonylurea (glimepiride)
Type 2 Diabetes
Recombinant tissue plasminogen activator (rt-PA)
Deep Vein Thrombosis
Tadalafil
Fontan Palliation
Surfactant
Infant, Newborn, Diseases
Pitavastatin
HIV
Entresto Pill
Congenital Heart Disease
Standard medical therapy
Heart Failure
amiodarone
Atrial Fibrillation
Standard antimicrobial therapy
Neutropenia
Low dose methotrexate
Vascular Inflammation
liothyronine
Heart Failure With Preserved Ejection Fraction
2-Hydroxybenzylamine
Atrial Fibrillation
TRIA-662
Hypertriglyceridemia
Lentiviral G1XCGD Gene Therapy
Granulomatous Disease, Chronic, X-linked
H1N1 vaccine high dose
H1N1 Influenza Virus
Sodium Nitroprusside (SNP)
Stress Disorders, Post-Traumatic
To Measure levels of circulating monocyte/ T cell doublets at Baseline
Post-Acute COVID-19 Syndrome
Maraviroc
Primary Graft Dysfunction
treosulfan
Accelerated Phase Chronic Myelogenous Leukemia
Perhexiline
Chronic Heart Failure
Levofloxacin
Sarcoidosis; Antimycobacterial Therapy
BIO-11006 Inhalation Solution
COPD
Atomoxetine
Sleep Apnea
Dapagliflozin 10 MG [Farxiga]
Chronic Kidney Diseases
Empagliflozin 10 MG
Obesity
Chelation therapy
Anemia (Iron-Loading)
Anakinra
Heart Failure With Normal Ejection Fraction
Epi-743
Methylmalonic Aciduria and Homocystinuria,Cblc Type
AMD3100
Fanconi Anemia
clopidogrel
Hypertension, Pulmonary
Aspirin
Acute Respiratory Distress Syndrome
Adult stem cells
Left Ventricular Dysfunction
Sodium Nitrite
Pulmonary Hypertension Secondary
Hematopoietic Stem Cell Transplant
Hemophagocytic Lymphohistiocytosis
Carbasalate calcium
Cerebral Hemorrhage
vitamin C
Cardiovascular Diseases
Magnesium Sulfate, Heptahydrate
Asthma
sugar pill
Heart Failure
Alendronic Acid
Calcific Aortic Stenosis
Recombinant human erythropoietin alfa (drug)
Myocardial Infarction
Oxygen
Obstructive Sleep Apnea
Atomoxetine and Oxybutynin (ato-oxy)
Obstructive Sleep Apnea
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UFH 250 U/kg or LMWH 100 U/kg sc twice daily | Phase 3 | Venous Thromboembolism | - | - |
LY3819253 | Phase 3 | Covid19 | - | - |
niacin | Phase 3 | Cardiovascular Diseases | - | - |
Eszopiclone | Phase 3 | Sleep Apnea | - | - |
Short storage RBC age | Phase 3 | Anemia | - | - |
Esomeprazole | Phase 3 | Asthma | - | - |
Tacrolimus | Phase 3 | Leukemia, Myelocytic, Acute | - | - |
tissue plasminogen activator | Phase 3 | Myocardial Infarction | - | - |
Hydrocortisone | Phase 3 | Infant, Newborn | - | - |
Omega-3 fatty acids (fish oil) | Phase 3 | Cardiovascular Disease | - | - |
daily fluticasone propionate | Phase 3 | Asthma | - | - |
Furosemide-Q12 hour bolus | Phase 3 | Heart Failure | - | - |
Vitamin D ergocalciferol | Phase 3 | Renal Function | - | - |
Secondary Prophylaxis | Phase 3 | Rheumatic Heart Disease | - | - |
Sulfonylurea (glimepiride) | Phase 3 | Type 2 Diabetes | - | - |
Recombinant tissue plasminogen activator (rt-PA) | Phase 3 | Deep Vein Thrombosis | - | - |
Tadalafil | Phase 3 | Fontan Palliation | - | - |
Surfactant | Phase 3 | Infant, Newborn, Diseases | - | - |
Pitavastatin | Phase 3 | HIV | - | - |
Entresto Pill | Phase 3 | Congenital Heart Disease | - | - |
Standard medical therapy | Phase 3 | Heart Failure | - | - |
amiodarone | Phase 3 | Atrial Fibrillation | - | - |
Standard antimicrobial therapy | Phase 3 | Neutropenia | - | - |
Low dose methotrexate | Phase 3 | Vascular Inflammation | - | - |
liothyronine | Phase 2 | Heart Failure With Preserved Ejection Fraction | - | - |
2-Hydroxybenzylamine | Phase 2 | Atrial Fibrillation | - | - |
TRIA-662 | Phase 2 | Hypertriglyceridemia | - | - |
Lentiviral G1XCGD Gene Therapy | Phase 2 | Granulomatous Disease, Chronic, X-linked | - | - |
H1N1 vaccine high dose | Phase 2 | H1N1 Influenza Virus | - | - |
Sodium Nitroprusside (SNP) | Phase 2 | Stress Disorders, Post-Traumatic | - | - |
To Measure levels of circulating monocyte/ T cell doublets at Baseline | Phase 2 | Post-Acute COVID-19 Syndrome | - | - |
Maraviroc | Phase 2 | Primary Graft Dysfunction | - | - |
treosulfan | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia | - | - |
Perhexiline | Phase 2 | Chronic Heart Failure | - | - |
Levofloxacin | Phase 2 | Sarcoidosis; Antimycobacterial Therapy | - | - |
BIO-11006 Inhalation Solution | Phase 2 | COPD | - | - |
Atomoxetine | Phase 2 | Sleep Apnea | - | - |
Dapagliflozin 10 MG [Farxiga] | Phase 2 | Chronic Kidney Diseases | - | - |
Empagliflozin 10 MG | Phase 2 | Obesity | - | - |
Chelation therapy | Phase 2 | Anemia (Iron-Loading) | - | - |
Anakinra | Phase 2 | Heart Failure With Normal Ejection Fraction | - | - |
Epi-743 | Phase 2 | Methylmalonic Aciduria and Homocystinuria,Cblc Type | - | - |
AMD3100 | Phase 2 | Fanconi Anemia | - | - |
clopidogrel | Phase 2 | Hypertension, Pulmonary | - | - |
Aspirin | Phase 2 | Acute Respiratory Distress Syndrome | - | - |
Adult stem cells | Phase 2 | Left Ventricular Dysfunction | - | - |
Sodium Nitrite | Phase 2 | Pulmonary Hypertension Secondary | - | - |
Hematopoietic Stem Cell Transplant | Phase 2 | Hemophagocytic Lymphohistiocytosis | - | - |
Carbasalate calcium | Phase 2 | Cerebral Hemorrhage | - | - |
vitamin C | Phase 2 | Cardiovascular Diseases | - | - |
Magnesium Sulfate, Heptahydrate | Phase 2 | Asthma | - | - |
sugar pill | Phase 2 | Heart Failure | - | - |
Alendronic Acid | Phase 2 | Calcific Aortic Stenosis | - | - |
Recombinant human erythropoietin alfa (drug) | Phase 2 | Myocardial Infarction | - | - |
Oxygen | Phase 2 | Obstructive Sleep Apnea | - | - |
Atomoxetine and Oxybutynin (ato-oxy) | Phase 2 | Obstructive Sleep Apnea | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in HeartSciences Inc.'s drug pipeline?→
CatalystAlert tracks 56 drug candidates in HeartSciences Inc.'s (HSCS) pipeline across Phase 3, Phase 2. Its lead program is UFH 250 U/kg or LMWH 100 U/kg sc twice daily (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HeartSciences Inc.'s next FDA catalyst?→
HeartSciences Inc.'s (HSCS) next tracked catalyst is a Phase 2 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HSCS biotech catalysts?→
Add HSCS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HeartSciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.